PR Newswire
JERSEY CITY, N.J., March 7, 2018
JERSEY CITY, N.J., March 7, 2018 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often
life-threatening infections, today announced that the Company will present at the 30th Annual ROTH Conference at the
Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 13, 2018 at 7:30
a.m. PT.
A live webcast will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two
hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients
suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies.
The SCYNEXIS team has
extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad
range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical
and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused
by Candida and Aspergillus species. For more information, visit www.scynexis.com.
C ONTACT:
I n ve s t o r Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com
Med i a Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com
View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-at-the-30th-annual-roth-conference-300609534.html
SOURCE SCYNEXIS, Inc.
